Core Viewpoint - The Hong Kong Innovative Drug ETF managed by Penghua experienced a decline of 2.30% on October 10, with a trading volume of 121 million yuan, indicating a challenging market environment for innovative drug investments [1] Fund Performance - The fund's latest net asset value is calculated at 538 million yuan, with a total share increase of 10 million shares on the same day, bringing the total shares to 559 million [1] - Over the past 20 trading days, the fund's shares have decreased by 41 million [1] - Since its inception on August 20, 2025, the fund has returned -3.67%, while the return over the past month is -5.25% [1] Management Information - The fund is managed by Penghua Fund Management Co., Ltd., with fund managers Lin Song and Zhang Yuxiang overseeing its operations [1]
10月10日港股创新药ETF鹏华（159286）份额增加1000.00万份
Xin Lang Cai Jing·2025-10-13 01:08